Averion’s Innovation Through Technology
With the average drug or biologic costing $1.2 billion dollars and now taking up to 10 years to get to market, everyday that a trial is delayed costs money. Averion continually seeks out innovative technologies to complete clinical trials and programs more rapidly. Averion identifies, evaluates, and qualifies all new potential technologies for consideration. Our staff is experienced in using the following technologies to assist our clients in running more cost-effective trials: